Cardiovascular Disease

Lerisetron (Standard) is the analytical standard of Lerisetron. This product is intended for research and analytical applications. Lerisetron is a potent 5-HT3 antagonists and possess high-affinity binding for the 5-HT3 receptors with pKi value of 9.2. Lerisetron has a potent ability to inhibit the 5-HT-evoked reflex bradycardia in urethane-anesthetized rats.

Metyrosine (Standard) is the analytical standard of Metyrosine. This product is intended for research and analytical applications. Metyrosine is a selective tyrosine hydroxylase enzyme inhibitor. Metyrosine exerts anti-inflammatory and anti-ulcerative effects. Metyrosine significantly inhibits high COX-2 activity. Metyrosine is a very effective agent for blood pressure control.

GATA4-NKX2-5-IN-1 (Standard) is the analytical standard of GATA4-NKX2-5-IN-1 (HY-103484). This product is intended for research and analytical applications. GATA4-NKX2-5-IN-1 (Compound 3) dose-dependently inhibits the GATA4–NKX2-5 transcriptional synergy with an IC₅₀ of 3 μM. GATA4-NKX2-5-IN-1 exhibits no activity on the protein kinases involved in the regulation of GATA4 phosphorylation, and it modulates the hypertrophic agonist-induced cardiac gene expression.

Moxonidine (Standard) is the analytical standard of Moxonidine (HY-B0374). This product is intended for research and analytical applications. Moxonidine (BDF5895) is an orally active imidazoline type 1 receptor (I₁-R) agonist. Moxonidine activates imidazoline I₁ receptors and α₂ adrenoceptors, affecting oxidized low-density lipoprotein uptake. Moxonidine reduces atherosclerotic lesions and lowers blood pressure. Moxonidine can be used in the study of hypertension, heart failure, and atherosclerosis.

BNC105P is a phosphate prodrug of BNC105 (HY-16114), that exhibits activity as a vascular disrupting agent (VDA) and an antitumor agent through conversion to active BNC105.

DHBP (dibromide) (Standard) is the analytical standard of DHBP (dibromide) (HY-101237). This product is intended for research and analytical applications. DHBP dibromide is an inhibitor for calcium release and a muscle relaxant.

Fluvastatin lactone, a lactone form of Fluvastatin (HY-14664), induces myotoxicity in human skeletal muscle cells.

Levobetaxolol (hydrochloride) (Standard) is the analytical standard of Levobetaxolol (hydrochloride). This product is intended for research and analytical applications.

Balovaptan (Standard) is the analytical standard of Balovaptan (HY-109024). This product is intended for research and analytical applications. Balovaptan (RG7314) is an orally available, selective brain-penetrant vasopressin 1a (hV1a) receptor antagonist, with K_is of 1 and 39 nM for human (hV1a) and mouse (mV1a) receptors, and is used for the research of autism.

Adibendan (BM 14478), a benzimidazole derivative, is an orally active, selective phosphodiesterase III (PDE III) activity inhibitor (IC₅₀=2.0 μM). Adibendan has IC₅₀ values more than 60-fold higher for the inhibition of PDE I or II. Adibendan is a new cardiotonic agent.

Nimodipine (Standard) is the analytical standard of Nimodipine. This product is intended for research and analytical applications. Nimodipine (BAY-e 9736) is an orally active, well-tolerated and light-sensitive dihydropyridine calcium antagonist. Nimodipine can be used for the research of cerebrovascular disorders.

CYM 50769 (Standard) is the analytical standard of CYM 50769 (HY-108624). This product is intended for research and analytical applications. CYM 50769 is a non-peptidic selective antagonist of neuropeptides B and W receptor 1 (NPBWR1). CYM 50769 can attenuates the NPW-23-induced cell proliferation in ATDC5. CYM 50769 can be used for researching endochondral bone formation.

Tranexamic acid-¹³C₆ (Cyclocapron-¹³C₆) is ¹³C labeled Tranexamic acid. Tranexamic acid (cyclocapron), a cyclic analog of lysine, is an orally active antifibrinolytic agent. Tranexamic acid attenuates the effects of severe trauma, inhibits urokinase plasminogen activator and ameliorates dry wrinkles. Tranexamic acid can used for the research of hemostasis .

Propargyl-DTM (P39) is an alkyne group molecule that can be used to modify antibodies or antibody fragments. Propargyl-DTM can be used in research on cancer, inflammatory diseases, and cardiovascular diseases.

Ap3A is a vasoactive molecule that regulates intracellular Ca²⁺ levels. Ap3A can promote the growth of vascular smooth muscle cells.

BMS 182874 hydrochloride is an orallyactive, highly selective endothelin receptor (ET_A receptor) antagonist, with IC₅₀ value of 0.150 μM, K_i of 0.055 μM. BMS 182874 hydrochloride reduces the arterial pressure of Deoxycorticosterone acetate (HY-B1472) induced hypertension model in rats, and can be used for cardiovascular disease research.

Enalaprilat (dihydrate) (Standard) is the analytical standard of Enalaprilat (dihydrate). This product is intended for research and analytical applications. Enalaprilat dihydrate (MK-422), the active metabolite of the oral proagent Enalapril, is a potent, competitive and long-acting angiotensin-converting enzyme (ACE) inhibitor, with an IC₅₀ of 1.94 nM. Enalaprilat dihydrate can be used for the research of hypertension.

BTZO-1 (Standard) is the analytical standard of BTZO-1 (HY-110084). This product is intended for research and analytical applications. BTZO-1, a chemical probe, binds to Macrophage migration inhibitory factor (MIF) with a K_d value of 68.6 nM, and its binding requires the N-terminal Pro1. BTZO-1 can activate antioxidant response element (ARE)-mediated gene expression and suppress oxidative stress-induced cardiomyocyte apoptosis in vitro.

2,5-Epidithia-3,6-dioxopiperazine (Formula 15) is a derivative of Epidithiodioxopiperazine (ETP). 2,5-Epidithia-3,6-dioxopiperazine improves intracellular penetration and restores the activity of 2-Cys-Prx (especially Peroxiredoxin II (PrxII)) of form simulation in cells. 2,5-Epidithia-3,6-dioxopiperazine inhibits PDGF-induced proliferation and migration in vascular smooth muscle cells while promoting these actions in endothelial cells with VEGF induction. 2,5-Epidithia-3,6-dioxopiperazine effectively inhibits the proliferation and migration and lung metastasis of melanoma cells. 2,5-Epidithia-3,6-dioxopiperazine can be used for vascular diseases such as hypertension, angina pectoris and myocardial infarction research.

Utibaprilat (FPL 63674XX) is a ACE inhibitor that is a major degradation product of Utibapril (HY-101681).